ACOG
NASDAQ HealthcareAlpha Cognition Inc. - Common Stock
Biotechnology
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
๐ Market Data
| Price | $8.84 |
|---|---|
| Volume | 366,866 |
| Market Cap | 192.48M |
| RSI (14-Day) | 53.6 |
| 200-Day MA | $6.36 |
| 50-Day MA | $7.68 |
| 52-Week High | $10.00 |
| 52-Week Low | $4.50 |
| Forward P/E | -14.79 |
| Price / Book | 3.08 |
๐ฏ Investment Strategy Scores
ACOG scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (45/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ACOG in your text
Paste any article, transcript, or post โ the tool will extract ACOG and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.